Authors

Latest:

Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.

Albert Grinshpun, MD, MSc

Latest:

Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer

Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.

Patricia Lugar, MD, MS, Duke Health

Latest:

Unmet Needs in SM Treatment

The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.

Rachel Kaufmann, PharmD

Latest:

LAG-3 Fills a Complex Role in the Immune System

The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.

Alan Tan, MD

Latest:

Dr Tan on the Efficacy and Safety of IO-IO and IO-TKI Combination Regimens in RCC

Alan Tan, MD, discusses the IO-based combination therapies that are available for the treatment of patients with RCC.

Guenther Koehne, MD, PhD

Latest:

Dr Koehne on the Use of Chemotherapy-Only Conditioning Regimens in Hematologic Malignancies

Guenther Koehne, MD, PhD, discusses the use of chemotherapy-only conditioning regimens for patients with hematologic malignancies undergoing transplant.

Daniele Robesti, MD

Latest:

Dr. Robesti on Optimizing Patient Selection for Salvage Lymph Node Dissection in Prostate Cancer

Daniele Robesti, MD, discusses how to optimize patient selection for salvage lymph node dissection in prostate cancer.

Philippe E. Spiess, MD, MS, FACS

Latest:

Dr. Spiess on Key Updates in the Management of Penile Cancer

Philippe E. Spiess, MD, MS, FACS, shares key updates in the management of patients with penile cancer.

Jan Joseph Melenhorst, BSc, MS, PhD

Latest:

Dr Melenhorst on the Evolving Understanding of CAR T-Cell Therapies in CLL

Jan Joseph Melenhorst, PhD, discusses the evolving understanding of the use of CAR T-cell therapies in the treatment of patients with chronic lymphocytic leukemia.

Boyu Hu, MD

Latest:

BTK Degraders and Other Targets in Mantle Cell Lymphoma

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center

Latest:

Dr. Efstathiou on the rPFS Benefit Achieved With Apalutamide Regimen in mCRPC

Eleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Kristin K. Zorn, MD

Latest:

PARP Inhibitor Therapy Options Are Transforming Landscape in Ovarian Cancer

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

Bertrand Arnulf, MD, PhD

Latest:

Dr Arnulf on Managing Tumor Burden for Improved PFS With Ide-Cel in R/R Myeloma

Bertrand Arnulf, MD, PhD, discusses the importance of managing tumor burden for improved outcomes with ide-cel in relapsed/refractory multiple myeloma.

Miguel Villalona-Calero, MD

Latest:

Dr Villalona-Calero on the Investigation of KB-0742 in Relapsed/Refractory Solid Tumors

Miguel Villalona-Calero, MD, discusses interim data from a phase 1/2 investigation of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma and highlights the ongoing evaluation of the agent’s safety.

Anne Angiolillo, MD

Latest:

Dr. Angiolillo on the Toxicity Profile of Traditional Treatment in Pediatric B-ALL

Anne Angiolillo, MD, discusses the adverse effects that are associated with traditional treatment in pediatric B-cell acute lymphoblastic leukemia.

Olufunmilayo Falusi Olopade, MD, FACP

Latest:

Dr. Olopade on Racial Disparities in Breast Cancer Outcomes

Olufunmilayo Falusi Olopade, MD, FACP, discusses racial disparities in breast cancer outcomes.

John N. Allan, MD

Latest:

Dr Allan on Efforts to Clarify the Optimal Treatment Sequence in CLL

John N. Allan, MD, discusses ongoing efforts to address areas of uncertainty regarding the optimal sequencing strategy in CLL.

Kate Kelley, MD, UCSF Health

Latest:

Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma

Swetha Kambhampati, MD

Latest:

Dr Kambhampati on the Rationale For Evaluating Real-World Outcomes With Brexu-Cel in MCL

Swetha Kambhampati, MD, discusses the rationale for evaluating outcomes with in a subgroup anlaysis of patients with relapsed/refractory mantle cell lymphoma, and how prior data from the phase 3 ZUMA-2 study supported the inception of this trial.

Siteman Cancer Center

Latest:

Whole Genome Sequencing for AML/MDS Risk Stratification

Two clinical trials for AML or MDS are open and enrolling at Siteman Cancer Center and Washington University School of Medicine in St. Louis.